A nominally significant difference in OS in favor of patients randomized to eribulin compared with control in patients with bone, lymph node, and chest wall/breast/skin metastases at baseline was observed.
← all excerpts
Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.
1
—
—